A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.
This is a Phase I/IIa Clinical Trial to Evaluate the Safety,Tolerability,Pharmacokinetics and Preliminary Effectiveness of IAE0972 in Patients With Advanced Malignant Solid Tumors.
Advanced Malignant Solid Tumor
DRUG: IAE0972
To evaluate the safety and tolerability of IAE0972 in Phase I, MTD/R2PD ,Incidence and frequency of DTL; AE，SAE occurrence and frequency (according to NCI CTCAE 5.0), 28 days after last medication, an average of 1 year|Objective response rate (ORR) in Phase IIa, To explore the effectiveness of IAE0972., Baeline until disease progression, assessed up to 36 months
Pharmacokinetic (PK) Cmax, PK parameters Cmax following single dose, after single dose , an average of 1 year|Pharmacokinetic (PK) Css,max, PK parameters Css,max following multiple doses, after multiple doses , an average of 1 year|Pharmacokinetic (PK) Css,min, PK parameters Css,min following multiple doses, after multiple doses , an average of 1 year|Pharmacokinetic (PK) Css,av, PK parameters Css,av following multiple doses, after multiple doses , an average of 1 year|Pharmacokinetic (PK) AUCss, PK parameters AUCss following multiple doses, after multiple doses , an average of 1 year|Pharmacokinetic (PK) CLss, PK parameters CLss following multiple doses, after multiple doses , an average of 1 year|Pharmacokinetic (PK) Vss, PK parameters Vss following multiple doses, after multiple doses , an average of 1 year|Pharmacokinetic (PK) R, PK parameters R following multiple doses, after multiple doses , an average of 1 year|Pharmacokinetic (PK) DF, PK parameters DF following multiple doses, after multiple doses , an average of 1 year|Pharmacokinetic (PK) Cmin, PK parameters Cmin following single dose, after single dose , an average of 1 year|Pharmacokinetic (PK) Tmax, PK parameters Tmax following single dose, after single dose , an average of 1 year|Pharmacokinetic (PK) AUC0-t, PK parameters AUC0-t following single dose, after single dose , an average of 1 year|Pharmacokinetic (PK) AUC0-∞, PK parameters AUC0-∞ following single dose, after single dose , an average of 1 year|Pharmacokinetic (PK) CL, PK parameters CL following single dose, after single dose , an average of 1 year|Pharmacokinetic (PK) Vd, PK parameters Vd following single dose, after single dose , an average of 1 year|Pharmacokinetic (PK) t1/2, PK parameters t1/2 following single dose, after single dose , an average of 1 year|Pharmacokinetic (PK) λz, PK parameters λz following single dose, after single dose , an average of 1 year|Objective response rate (ORR) (Phase I ), To explore the preliminary effectiveness of IAE0972., Baeline until disease progression or death, an average of 1 year|Overall survival (OS) (Phase I ), To explore the preliminary effectiveness of IAE0972., Baeline until disease progression or death, an average of 1 year|Disease control rate (DCR) (Phase I ), To explore the preliminary effectiveness of IAE0972., Baeline until disease progression or death, an average of 1 year|To evaluate the Immunogenicity of IAE0972 in patients with advanced malignant solid tumors (Phase I ), The frequency of anti-drug antibodies(ADA) against IAE0972, Before each administration of dose cycle，an average of 1 year|Progression-free survival（PFS) in Phase II, To explore the effectiveness of IAE0972., Baeline until disease progression or death,assessed up to 36 months|Overall survival (OS)in Phase II, To explore the effectiveness of IAE0972., Baeline until disease progression or death,assessed up to 36 months|Disease control rate (DCR) in Phase II, To explore the effectiveness of IAE0972., Baeline until disease progression or death,assessed up to 36 months|Immunogenicity of IAE0972 (Phase II ), The frequency of anti-drug antibodies(ADA) against IAE0972, Before each administration of dose cycle,assessed up to 36 months|Incidence of adverse event (AEs) and SAEs (Phase II), To investigate the safety characteristics, After last medication,assessed up to 36 months
The study includes three phases: dose escalation (Phase Ia), dose extension (Phase Ib), and clinical exploration (Phase IIa).First, the Phase Ia dose escalation will be carried out. After finishing the Phase 1a dose escalation, the Phase Ib dose extension study can be carried out in the MTD dose which is obtained from Phase 1a . After Phase Ia \&1b are completed and RP2D is obtained, Phase IIa clinical exploratory research can be carried out.